| First Author | De Leon JH | Year | 1995 |
| Journal | Drug Metab Dispos | Volume | 23 |
| Issue | 12 | Pages | 1354-61 |
| PubMed ID | 8689943 | Mgi Jnum | J:31250 |
| Mgi Id | MGI:78747 | Citation | De Leon JH, et al. (1995) Slow acetylation in mice is caused by a labile and catalytically impaired mutant N-acetyltransferase (NAT2 9). Drug Metab Dispos 23(12):1354-61 |
| abstractText | Three N-acetyltransferase genes (NAT*) were detected in inbred parental and congenic mice, Direct sequencing of NAT2* and liver cytosolic N-acetylation activity determinations with NAT2-specific (p-aminobenzoic acid) and NAT2-selective (2-aminofluorene) substrates have established that the acetylator congenic A.B6 and B6.A mice are genotypically and phenotypically identical to the parental B6 (''wild-type''; rapid acetylator) and A (mutant; slow acetylator) mice, respectively, from which they originated, The apparent K-M for p-aminobenzoic acid and thermal inactivation rates determined with liver cytosol from the mutant (A and B6.A) mice were 3-fold and one order of magnitude higher than the corresponding values with liver cytosol from the wild-type (B6 and A,B6) strains, Northern blotting and immunoblotting revealed hepatic NAT2 mRNA and protein bands of equal size and intensity, regardless of the NAT2* genotype or phenotype of the animals. Incubation of liver cytosol from mutant A and B6.A mice at 37 degrees C for 6 hr resulted in virtual cessation of p-aminobenzoate N-acetylation activity, whereas the steady-state level of immunoreactive NAT2 remained unchanged, The results indicate that the amino acid change (N991) in mutant NAT2* from slow acetylator mice does not hinder the synthesis of hepatic NAT2 protein, but, rather, leads to production of a conformationally modified NAT2 molecule that resists degradation by tissue proteases but is labile and catalytically impaired. |
